Devyser Genomic Laboratories signs first commercial agreement
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first commercial agreement with UK based diagnostics company Cyted. The initial period for the agreement is two years with estimated total revenue amounting up to approximately 25 MSEK where of approximately up to 6 MSEK in 2024.
Devyser CEO Fredrik Alpsten commented: "This agreement, our first external commercial agreement, shows the large potential with our state-of-the-art CLIA-certified Next Generation Sequencing laboratory. Running tests for partners is one of the main purposes of the laboratory. The other main purpose of the laboratory is to offer tests to hospitals and laboratories as a service”.
Cyted CEO and Co-Founder Marcel Gehrung commented: “This is an important step as Cyted expands its operations into the United States. Devyser Genomic Laboratories' expertise and capabilities will be pivotal as we introduce the Heartburn Health Check using our minimally invasive test, EndoSign®, into new markets. I look forward to working with the team and delivering to those who would benefit from our innovative diagnostic technology.”
Devyser established the US CLIA-certified laboratory, Devyser Genomic Laboratories (https://lab.devyser.com), during the spring of 2023 and received CLIA certification from the Centers for Medicare and Medicaid Services (CMS) in May 2023. The laboratory is based in Atlanta, Georgia.